CTOR

News

prnewswire.comCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignanciesprnewswire.comJun 1

prnewswire.comCitius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meetingprnewswire.comMay 26

prnewswire.comCitius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Updateprnewswire.comMay 15

prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Updateprnewswire.comMay 15

prnewswire.comCitius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercializationprnewswire.comMay 5

Trade CTOR

About Citius Oncology, Inc.

Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.

CEO: Leonard L. Mazur
IPO Date: Dec 8, 2022

Market Data

Open: $0.69
High: $0.72
Low: $0.6633
Volume: 31.1K
52W High: $6.19
52W Low: $0.491

Valuation

Market Cap: $65M
Enterprise Value: $66M

Financials

Free Cash Flow: $-5.5M
Revenue: $0
Net Income: $-25M
Cash: $3.9M
Debt: $3.8M

Events

EarningsAug 18

EPS est. -0.04